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High-Sensitivity Troponin
Practical Advice for Clinicians*James L. Januzzi, JR, MDEverything must be made as simple as possible.
But not simpler.
—Albert Einstein (1)T he path to the high-sensitivity cardiactroponin (hs-cTn) assays has taken morethan 2 decades. Historically, after early
studies showing superior diagnostic and prognostic
performance compared with creatine kinase isoen-
zymes, conventional cTnI and T were adopted as
gold standard biomarkers to evaluate patients with
suspected acute coronary syndrome (ACS). Subse-
quently, work by the Third Global Myocardial In-
farction Task Force (2) and others began to focus on
exactly what deﬁned an abnormal cTn, recognizing
that ACS patients experienced a worse prognosis at
cTnI or T concentrations below these biomarkers’
reference limits for myocardial infarction (MI) di-
agnosis. Indeed, any measurable cTnI or T in the
context of an ACS appeared to portend a worse prog-
nosis (3), suggesting the need to reconsider reference
ranges for both biomarkers. Accordingly, consensus
developed that upper reference limits for cTnI or T
should be predicated on the 99th percentile of a
healthy normal population (2).
However, an important conundrum existed: al-
though the risk of ACS complications appears at
very low levels of cTnI or T, such concentrations*Editorials published in the Journal of the American College of Cardiology
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Ingelheim.produced unacceptably high imprecision in conven-
tional cTnI or T assays. Thus, the need existed for
cTn assays with greater precision at low analyte
concentrations; this ultimately led to development of
hs-cTn methods.
The hs-cTn immunoassays are frequently based on
the same antibodies used in conventional cTnI or
T assays, but, through changes in how the assays
are run, allow precise detection of very low con-
centrations of cTnI or T. When testing blood samples
of normal, healthy individuals (where conventional
methods are routinely negative), hs-cTn methods may
detect a signal in a majority of these individuals
and can do so with high precision at the 99th per-
centile of a normal population.
In patients with acute MI, hs-cTnI or T are often
abnormal earlier than conventional cTn methods,
allowing for more rapid diagnostic evaluation (4–6);
as soon as 2 h after presentation, a substantial per-
centage of patients can be evaluated accurately with
hs-cTn. Additionally, hs-cTn assays detect acute MI in
up to 25% of ACS patients with normal conventional
cTn values who are thought to have unstable angina
(UA). Beyond its enhanced diagnostic sensitivity, hs-
cTn has also been proven superior to conventional
cTn for prognosis. Thus, hs-cTn methods represent a
major advance.
However, in laboratory medicine, when a test has
enhanced sensitivity, the risk of loss of speciﬁcity
increases. Indeed, with improved sensitivity, hs-cTn
methods now detect previously unrecognized myo-
cardial necrosis in many acute and chronic cardio-
vascular conditions, confounding interpretation and
confusing clinicians (Figure 1). Make no mistake, such
abnormal values reﬂect myocardial injury, but the
clinician is faced with important questions: Are these
values due to an acute MI? Or do they arise from some
other cause of myocardial injury, such as heart
FIGURE 1 Overlap Between Myocardial Injury, Necrosis, and Infarction
Various clinical entities can present as one or more of these categories. Detection of
myocardial necrosis does not necessarily inform the presence of myocardial necrosis.
Reprinted with permission from Thygesen et al. (2).
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1666failure–related subendocardial injury? If a patient
does not obviously have an acute MI but has
increased hs-cTn, is this even important?SEE PAGE 1655In this issue of the Journal, investigators from the
SWEDEHEART (Swedish Web-System for Enhance-
ment and Development of Evidence-Based Care in
Heart Disease Evaluated According to Recommended
Therapies) registry addressed these questions (7); in
this analysis, 48,594 patients with symptoms sug-
gestive of ACS admitted to a coronary intensive care
unit or specialized unit were studied. Of these pa-
tients, 47.3% had an acute MI, whereas 23.2% had
UA. The investigators divided subjects into 4 groups
based on their maximal hs-cTnT value during hos-
pitalization: those with hs-cTnT below the detection
limit of 6 ng/l, those with hs-cTnT between 6 and
13 ng/l (measurable, but normal), those with hs-cTnT
above the 99th percentile of 14 ng/l but below 50 ng/l
(abnormal by hs-cTn standards, but below the level
where a conventional cTn would be abnormal),
and then $50 ng/l (a range where both hs-cTnT
and conventional cTnT are abnormal). Notably,
across these categories, clinical risk factors, de-
mographics, extent of disease, and severity of pre-
sentation worsened: with each increase in hs-cTnT
came a parallel increase in medical complexity and
clinical risk.Speciﬁcally focusing on the 10,476 patients with an
hs-cTnT between the 99th percentile of 14 ng/l and
50 ng/l (a group that would have been called troponin
negative using conventional cTnT methods), hs-cTnT
reclassiﬁed 18.2% from UA to acute MI, revealing the
incremental sensitivity of hs-cTnT. However, most
patients with an abnormal hs-cTnT did not have an
acute MI, raising justiﬁable concerns about the ram-
iﬁcations of lower speciﬁcity for the diagnosis. Are
these false positives? Perhaps, from the point of view
of an acute ischemic coronary event, but clearly such
low level hs-cTnT increases are not benign: the
SWEDEHEART investigators demonstrated very sim-
ply but elegantly that the risk of mortality began to
increase right above the threshold of 14 ng/l, regard-
less of diagnosis, and prognosticated well in women
as well as elderly patients. Thus, irrespective of an MI
diagnosis, patients with an abnormal hs-cTnT value
are indeed at higher risk and should be considered as
such.
Caveats for this analysis clearly exist. First, this is a
highly selected population of higher risk patients
admitted to specialized coronary units with a high
likelihood of an ACS diagnosis. Indeed, in this anal-
ysis, of those below the hs-cTnT detection limit of
6 ng/l (which some suggest identiﬁes an ultralow-risk
population), 2.2% of 5,790 patients received a diag-
nosis of acute MI (something the investigators do not
explain), whereas an additional 28.3% had a diagnosis
of UA, a ﬁnding that contradicts the growing belief
that ultralow hs-cTn values predict a low rate of ACS
(4,5). The analysis used the highest recorded hs-cTnT
value rather than considering serial measurements;
seeking a signiﬁcant increase and/or decrease in hs-
cTn has been suggested to best inform the presence
of acute MI, whereas more chronic increases without
a change in serial measurement may be seen in non-
ischemic syndromes.
What’s a clinician to do then? On the one hand, we
have a tool with substantially greater sensitivity to
diagnose acute MI and with outstanding ability to
predict a poor prognosis. On the other hand, these
assays detect myocardial necrosis from other disease
states and conditions, so speciﬁcity for acute MI may
be challenged.
It is critical for physicians to remember that an
abnormal hs-cTnI or T value only informs the pres-
ence of myocardial necrosis, not its mechanism; cli-
nicians must carefully consider the differential
diagnosis for an abnormal hs-cTn value just as they
do for abnormal values of other diagnostic tests and
only make a diagnosis of acute MI if evidence of
myocardial ischemia is present. As noted, serial
measurement over a short period of time may be
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1667informative regarding rapid increases and/or de-
creases in hs-cTn characteristics of acute MI.
Considering hs-cTn as a quantitative rather than
qualitative measure will be important, too: the days
of a patient being referred to as “troponin positive”
should end, and clinicians should now consider the
potential diagnoses seen in the hs-cTn range detec-
ted. Finally, determining the appropriate workup for
patients with abnormalities in hs-cTn values will
be necessary. Yes, there will be more testing and
treatment done in these patients, but in theory,
thanks to the focus drawn to them through recogni-
tion of an abnormal hs-cTn value, such management
will likely be more cost-effective given the higher risk
status of such patients and may well lead to improved
outcomes.There will be a learning curve as we gain experi-
ence with hs-cTnI or T. It is reasonable to expect
that the advent of hs-cTn testing will inevitably
be accompanied by growing pains; some may call for
the simpler paradigm afforded by conventional cTn.
In this case, however, simpler is not better: more
rapid and sensitive detection of acute MI coupled
with greater prognostic value from hs-cTn testing
makes it worth the effort to become acquainted with
its use.
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